Il-Yang Pharm. Co., Ltd.
Clinical trials sponsored by Il-Yang Pharm. Co., Ltd., explained in plain language.
A pharmaceutical company developing and marketing prescription drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IY-828026 tested in healthy people for first time Results expected Mar 2027 (estimated)
- Can a new pill rescue patients when standard leukemia drugs stop working? Results expected Jun 2027 (estimated)
- Can a lower dose of a leukemia drug keep the disease in check? Results expected Jul 2027 (estimated)
-
Can a leukemia drug slow Parkinson's disease?
Disease control OngoingResearchers are testing whether radotinib, a drug used for leukemia, can help people with Parkinson's disease. The trial will give the drug or a placebo to about 43 adults aged 40 to 80 who were diagnosed within the past three years. The study measures safety, how the drug moves …
Phase 2 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a lower dose of a leukemia drug keep the disease in check?
Disease control OngoingThis study tests whether reducing the dose of the cancer drug radotinib can still control chronic myeloid leukemia in its early phase while possibly easing side effects. Adults newly diagnosed with this blood cancer take a lower dose twice daily for up to a year. Researchers meas…
Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a newer drug outperform the standard for chronic myeloid leukemia?
Disease control OngoingThis phase III trial compares two oral drugs, radotinib and imatinib, in adults newly diagnosed with chronic myeloid leukemia in its chronic phase. Researchers want to see if radotinib, taken twice daily, achieves a deeper molecular response at 12 months than imatinib, taken once…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC